Current Report Filing (8-k)
February 17 2021 - 8:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event
reported): February 16, 2021
electroCore, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-38538
|
|
20-3454976
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification Number)
|
200 Forge Way, Suite 205
Rockaway, NJ 07920
(Address of principal executive offices
and zip code)
(Former name or former address, if changed
since last report.)
(973) 290-0097
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, Par Value $0.001 Per Share
|
|
ECOR
|
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01. Other Events.
On February 16, 2021, electroCore, Inc.
issued a press release announcing that gammaCoreTM non-invasive vagus nerve stimulation was cleared by the U.S. Food
and Drug Administration under Section 510(k) of the Federal Food and Drug Act for the treatment of migraine in adolescents between
12 and 17 years of age. A copy of the press release is filed herewith as Exhibit 99.1.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
electroCore, Inc.
|
|
|
February 17, 2021
|
/s/ Brian Posner
|
|
Brian Posner
|
|
Chief Financial Officer
|
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Apr 2023 to Apr 2024